The nearly $1 billion won by VirnetX in patent trials against Apple Inc. exists under a cloud since the Patent Trial and Appeal Board has found the patents invalid. With appeals pending from the board's decisions and one of the trials, here's a look at VirnetX's arguments that the patents shouldn't have been reviewed, and Apple's efforts to flip the verdict.
TiVo, a vendor of digital video recorders, is bracing for a legal battle with entertainment companies over a technology that would allow users to watch copies of television programs and films on devices outside their homes.
Online auction exchange eBay and telecom carrier AT&T Corp. have agreed to settle a patent-infringement lawsuit that AT&T brought against eBay's PayPal electronic-payment service last year.
A European Commission review of current copyright legislation promises to fine-tune the law rather than overhaul the European Union’s legal framework for copyrights.
Comic book publisher Marvel Enterprises has filed a lawsuit against entertainment giant Walt Disney Co., seeking almost $55 million over royalty payments for Spider-Man and other animated television series.
Several members of the European Competitiveness Council have said they voted for the European Union's Software Patent Directive "by mistake" in May and are now seeking ways of reversing their positions.
The University of California and Eolas have filed a brief with the U.S. Court of Appeals for the Federal Circuit to counter Microsoft's request for an appeal of a $565 jury verdict.
Canadian telecom company Nortel Networks Corp. has filed a lawsuit against U.S. rival Arbinet-thExchange Inc over alleged copyright infringement and trade secret misappropriations.
Israeli drug maker Teva Pharmaceuticals has filed an application to make a generic version of Sanofi-Synthelabo’s hypertension drug Avapro.
In a setback for U.S. drug maker Merck, the European Patent Office has revoked the European patent for Fosamax Once Weekly, Merck’s hormone treatment for osteoporosis and other bone-weakening diseases.
A London-based intellectual property licensing company has sued Apple Computer Inc. and Microsoft Corp. over patents for automatic software updates.
Application switch vendor Radware has filed a lawsuit against rival F5 Networks for infringing on a patent for a technology used to determine the proximity of networked devices.
The European Union's Office for Harmonization in the Internal Market has rejected Czech brewer Budejovicky Budvar’s attempt to block Anheuser-Busch's registration for the trademark "Bud" for entertainment and related services, the U.S. brewer said.
The American Chamber of Commerce has joined forces with Pfizer in protesting China’s annulment of the drug maker's patent for Viagra, questioning China’s commitment to protecting intellectual property.
Abbott Laboratories has settled two lawsuits over the pricing of Norvir, the anti-HIV drug targeted for a compulsory license by activists and patient groups.
A U.S. District Court Judge has ruled that Kodak did not give adequate warning of potential infringements in some of its claims against German rival Agfa, but nonetheless rejected Agfa’s motion to have the patent lawsuit dismissed.
A California subsidiary of telecom operator Verizon has settled a patent lawsuit brought by Ronald A. Katz Technology Licensing LP (RAK) over computer telephony technology.
The Federal Circuit has upheld a lower court’s decision to invalidate a cooking patent held by ConAgra, but set aside a related $18 million antitrust award determined by the district court jury.
Microsoft Corp. has agreed to pay Lindows.com Inc. $20 million to settle a legal dispute over whether the name of the Linux operating system was too similar to the Windows trademark, the companies said.
A U.S. district court has granted Inverness Medical Innovations’ motion for summary judgment of infringement and issued a preliminary injunction against Acon Laboratories in Inverness’ patent lawsuit over immunoassay tests.
Indian drug maker Dr. Reddy’s has made a preliminary filing with the U.S. Food and Drug Administration, paving the way for an application for a generic version of AstraZeneca's blockbuster heartburn medicine Nexium.